X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Advanz get the rights to a portfolio of alprostadil products including, Prostavasin, Viridal, Vasaprostan and Edex, which consists of injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease, in 20 countries.
Lead Product(s): Alprostadil
Therapeutic Area: Psychiatry/Psychology Product Name: Prostavasin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: $96.0 million Upfront Cash: $96.0 million
Deal Type: Acquisition April 01, 2020
Details:
The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.
Lead Product(s): Alprostadil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: $98.0 million Upfront Cash: $84.0 million
Deal Type: Agreement March 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
